Breast Cancer
U.S. Food and Drug Administration approves InSite HER-2/neu (CB11) monoclonal antibody
Published in Medical Letter on the CDC and FDA, November 6th, 2005
This antibody is used in tests to identify breast cancer patients eligible for treatment with the cancer drug Herceptin (Trastuzumab). InSite HER-2/neu (CB11) is available as a ready-to-use reagent, in manual and automated formats, and is allowed for use with BioGenex Super Sensitive Detection Systems. The automated format is approved for use on the BioGenex i6000 Automated Staining System and the Optimax Plus Consolidated Staining System.
Both manual and automated versions of InSite...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Hemophilia Therapy
Republic of Georgia develops successful national hemophilia program - Measles Vaccine
Measles control program reduces measles deaths by 20% in Africa - Natural Products
Russian ethnomedicinal plants more cytotoxic than established therapies - Neural Tube Defects
Prevalence of spina bifida and anencephaly declining in U.S. minorities - Sexually Transmitted Diseases
Phone call more cost-effective than counseling for prompting follow-up clinic visits - Adverse Drug Reaction
Agencies issue alert on Menactra meningococcal vaccine and Guillain Barre syndrome - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
